Navigation Links
Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
Date:6/8/2009

," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the SEC on May 11, 2009, as well as other filings by the company with the SEC.


'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
2. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
3. Clinical Data Published in Science Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
4. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
5. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
6. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
7. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
8. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
9. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
10. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
11. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 Research and Markets ... Diagnostic Devices Market 2014-2018" report to their offering. ... About Ophthalmic Diagnostic Device An ophthalmic ... a defect or deficiency in the human visual pathway. ... such as presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, and ...
(Date:7/25/2014)... Ore. , July 25, 2014  Semler ... an emerging medical risk assessment company that develops ... patients and evaluating chronic diseases, today reported financial ... ended June 30, 2014. "The ... for Semler," said Doug Murphy-Chutorian , M.D., ...
(Date:7/25/2014)... , July 25, 2014  Arena Pharmaceuticals, Inc. ... provide a corporate update and report second quarter 2014 ... on Friday, August 1, 2014. That same day, Arena ... a.m. Eastern Time (5:30 a.m. Pacific Time). ... 877.643.7155 for domestic callers and 914.495.8552 for international callers. ...
Breaking Medicine Technology:Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3
... 10, 2011 Sildenafil, a drug used to ... possible use -- helping children and young adults ... Sildenafil significantly improved measures of exercise performance during ... according to researchers from The Children,s Hospital of ...
... seek ways to reduce Medicaid spending, they should start by ... model to the more efficient model used in some parts ... finds that the program could save $473 million over ... more like those in Medicare and commercial plans. Governors Chris ...
Cached Medicine Technology:Exercise Performance in Children and Young Adults with Single Ventricle Heart Disease Improves with Use of Drug for Erectile Dysfunction 2Exercise Performance in Children and Young Adults with Single Ventricle Heart Disease Improves with Use of Drug for Erectile Dysfunction 3Budget Solution? Modernizing Medicaid Pharmacy Could Save Florida $473 Million 2
(Date:7/26/2014)... July 26, 2014 As the ... the true vision of Xoçai is ... its exclusive and healthy chocolate products. One such ... of cacao, açaí berries and blueberries, an ingredient ... high-antioxidant blend is utilized in all of Xoçai ...
(Date:7/25/2014)... Dental Perfection, a Derby cosmetic dentist ... general dentistry, clear braces and much more, has just ... in Derby. The new practice, which is scheduled to ... in Littleover, Derby. Patients may already pre-register for the ... dental practice, which is headed by Invisalign specialist and ...
(Date:7/25/2014)... Dallas, Texas (PRWEB) July 26, 2014 ... Global and China Gel Permeation Chromatography Industryā€¯ ... on the Global and China Gel Permeation ... Permeation Chromatography information, including Gel Permeation Chromatography ... as well as industry overview. This research ...
(Date:7/25/2014)... July 25, 2014 In recent years, men ... eager to reverse the symptoms associated with age-related testosterone decline. ... at large, a new case study from Renew ... of testosterone therapy using bioidentical hormones. , The case ... from Seattle who found himself beginning to feel the effects ...
(Date:7/25/2014)... American motor vehicle owners who are at higher ... premiums for vehicle insurance on average. The Quotes Pros ... SR22 insurance for high risk motorists this year at ... of local agencies providing direct price quotations for risk ... available for any car owner to access. One advantage ...
Breaking Medicine News(10 mins):Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 2Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 3Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 4Health News:Derby Cosmetic Dentist Dental Perfection to Open New Practice in Littleover, Derby this September 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:SR22 Insurance for High Risk Motorists Added to Local Quotes System at Insurer Website Online 2
... , , , ... Costs Will Increase , , ... Director Douglass Elmendorf about current legislative drafts proposed by the Senate and ... care costs in the U.S. -- chronic disease. , ...
... the treatment of disease ,The team, led ... Research at the University of Copenhagen and the Max Planck ... in 1,750 different proteins. "This is more than ... of known acetylation switches by a factor of six, and ...
... prevention, treatment and care throughout Europe by improving communications within ... the launch of a new website: www.eurocancercoms.eu . The ... from researchers and doctors to patients. The ... Oncology and is led by ECCO the European CanCer ...
... only four sites across the country to participate in a ... investigate the effectiveness of a chemotherapeutic agent, ThermoDox, used in ... treating recurrent chest wall breast cancer. Recurrent chest ... on the chest wall, most commonly presenting in the skin ...
... are diagnosed with pancreatic cancer. Few live very long, ... after diagnosis. There,s new hope, though, from the ... University,s Faculty of Life Sciences. His drug compound Salirasib ... passed Phase I/II clinical trials. The drug, given in ...
... at Ben-Gurion University of the Negev (BGU) have conducted a ... adolescents, demonstrating that strong social support from friends is a ... to be the first of its type, was published in ... The American Academy of Pediatrics. ...
Cached Medicine News:Health News:PFCD Urges Congress to Address Real Cost-Driver in Health Reform in Light of New CBO Statement 2Health News:New Web site launches $1.7 million project to improve European cancer communications 2Health News:New Web site launches $1.7 million project to improve European cancer communications 3Health News:RI Hospital first in country to enroll patient in new study for recurrent chest wall breast cancer 2Health News:New drug candidate prolongs the lives of pancreatic cancer patients 2Health News:Social support buffers adolescent depression after terrorist attacks: Ben-Gurion University 2
PDA format of the well-known standard antimicrobial reference....
PDA application providing a complete guide for the diagnosis and management of electrolyte disorders....
Contains the most common procedures from all orthopedic sub-specialties organized by body area....
Consists of the print and PDA versions of Harrison's Manual of Medicine 15th Edition. Provides high-end medical content via PDA....
Medicine Products: